There is, of course, more work to be done in individual European countries to ensure access and to educate both the patient and medical communities.
According to the press release:
The European Marketing Authorization is valid in the 28 countries of theYou can read the whole release here: http://ir.ultragenyx.com/news-releases/news-release-details/kyowa-kirin-and-ultragenyx-announce-crysvitar-burosumab-receives
European Unionand in Norway, Iceland and Liechtenstein. The first commercial launch of Crysvita is expected to take place in Germany in the second quarter of 2018, followed by other European countries.